In the latest trading session,, 0.4 million Elanco Animal Health Inc (NYSE:ELAN) shares changed hands as the company’s beta touched 1.50. With the company’s most recent per share price at $9.59 changing hands around $0.13 or 1.32% at last look, the market valuation stands at $4.76B. ELAN’s current price is a discount, trading about -96.04% off its 52-week high of $18.80. The share price had its 52-week low at $8.02, which suggests the last value was 16.37% up since then. When we look at Elanco Animal Health Inc’s average trading volume, we note the 10-day average is 5.31 million shares, with the 3-month average coming to 5.19 million.
Analysts gave the Elanco Animal Health Inc (ELAN) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.87. If we narrow down to specifics, the data shows that 1 out of 5 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended ELAN as a Hold, 3 felt it is a Buy and 0 rated the stock as Underweight. Elanco Animal Health Inc’s EPS for the current quarter is expected to be 0.3.
Elanco Animal Health Inc (NYSE:ELAN) trade information
Instantly ELAN is in green as seen in intraday trades today. With action 13.03%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -20.85%, with the 5-day performance at 13.03% in the green. However, in the 30-day time frame, Elanco Animal Health Inc (NYSE:ELAN) is -11.33% down. Looking at the short shares, we see there were 21.85 million shares sold at short interest cover period of 4.13 days.
The consensus price target for the stock as assigned by Wall Street analysts is 14, meaning bulls need an upside of 31.5% from its recent market value. According to analyst projections, ELAN’s forecast low is 12 with 18 as the target high. To hit the forecast high, the stock’s price needs a -87.7% plunge from its current level, while the stock would need to soar -25.13% for it to hit the projected low.
Elanco Animal Health Inc (ELAN) estimates and forecasts
Year-over-year growth is forecast to reach 1.29% up from the last financial year.
Consensus estimates given by 8 financial analysts project the company’s revenue in the current quarter to hit an average of 1.17B. 8 analysts are of the opinion that Elanco Animal Health Inc’s revenue for the current quarter will be 1.18B. The company’s revenue for the corresponding quarters a year ago was 1.21B and 1.18B respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -3.15%. The estimates for the next quarter sales put growth at -0.51%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 29.95%. The 2025 estimates are for Elanco Animal Health Inc earnings to decrease by -10.08%, but the outlook for the next 5-year period is at 5.81% per year.
ELAN Dividends
Elanco Animal Health Inc is expected to release its next quarterly earnings report on 2025-Feb-24.
Elanco Animal Health Inc (NYSE:ELAN)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 1.03% of Elanco Animal Health Inc shares while 100.13% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 101.18%. There are 100.13% institutions holding the Elanco Animal Health Inc stock share, with DODGE & COX the top institutional holder. As of 2024-06-30, the company held 16.9128% of the shares, roughly 83.58 million ELAN shares worth $1.21 billion.
PRIMECAP MANAGEMENT CO/CA/ holds the second largest percentage of outstanding shares, with 10.6845% or 52.8 million shares worth $761.94 million as of 2024-06-30.
Among Mutual Funds, the top two as of Dec 31, 2024 were Dodge & Cox Funds-Dodge & Cox Stock Fund and VANGUARD CHESTER FUNDS-Vanguard PRIMECAP Fund . With 55.34 shares estimated at $529.62 million under it, the former controlled 11.15% of total outstanding shares. On the other hand, VANGUARD CHESTER FUNDS-Vanguard PRIMECAP Fund held about 3.82% of the shares, roughly 18.98 shares worth around $181.63 million.
